INTRODUCTION

Junctional rhythms originate from the atrioventricular (AV) junction. They encompass a wide spectrum of arrhythmias with variable clinical presentations, significance, and treatment strategies. Junctional ectopic tachycardia (JET) was first described by Coumel et al. in 1976 as a distinct entity and is an automatic focus rhythm most commonly seen in children.

JET is recognized on the surface electrocardiogram (ECG) by a narrow QRS tachycardia, with AV dissociation (although AV association may be rarely present) and a faster ventricular rate. JET occurs in two distinct clinical settings: (i) a permanent form, a primary idiopathic disorder during infancy called the congenital JET, and (ii) a transient form, in children and also in adults immediately after surgery for congenital heart disease (CHD), called the postoperative form. Isolated cases of JET following viral myocarditis have also been reported.

CONGENITAL JUNCTIONAL ECTOPIC TACHYCARDIA

The congenital form of this pathology is discussed briefly however is not the main focus of the review. Congenital JET is rare, accounting for <1% of pediatric arrhythmias, and usually occurs in infants <6 months of age. It has a familial predisposition in around 50% of cases, commonly presents with cardiomegaly, congestive heart failure, and echocardiographic...
evidence of left ventricular dysfunction, and has a mortality rate as high as 34%. A pharmacologic approach is regarded as the first-line therapeutic option for infants with symptoms, reduced ventricular function, or rapid heart rate. Digoxin, amiodarone, propranolol, and flecainide have been used alone or in combination. More recently, ivabradine, the selective and specific inhibitor of the cardiac pacemaker current (If), has been found useful in resistant cases. Successful transcatheter ablation has been reported with preservation of normal AV conduction and is suggested for drug refractory cases. A few cases of sudden death have been attributed to evolution to complete heart block, unrelated to ablation procedures. Prophylactic pacemaker implantation is controversial. Permanent pacemaker implantation is largely indicated for AV block secondary to ablation procedures. Documented AV block, either on ECG, Holter or on transesophageal electrophysiological test, might warrant permanent pacemaker implantation. Improved outcomes with a mortality rate of 4% have been reported with current therapies, which mainly consist of medical management (primarily amiodarone), radiofrequency and cryoablation, and permanent pacemaker implantation.

**POSTOPERATIVE JUNCTIONAL ECTOPIC TACHYCARDIA**

This is the most common form of JET, usually occurring in the first 24–48 h after surgery. Postoperative JET is associated with increased risk of morbidity and mortality. Grosse-Wortmann et al. described JET as typically occurring 2–8 days after cardiopulmonary bypass (CPB). JET has also been rarely documented after the 1st week of surgery. The mean cardiac intensive care unit stay and the mean mechanical ventilation time have been reported to be high for patients who developed JET in the postoperative period compared to those who did not. JET is a self-limiting disorder that usually resolves within 1 week. Onset is at a time when the systolic and diastolic function of the heart is generally impaired. The rapid heart rate and loss of AV synchrony lead to decreased cardiac output and increased central venous pressure, which result in multiorgan dysfunction. The reduced cardiac output stimulates the adrenergic system, which in turn further accelerates the heart rate. This rapidly evolves into a vicious hemodynamic spiral. Hence, postoperative JET warrants prompt treatment. Incidence, mostly based on surface ECGs, varies from 1% to 10%. Mortality was high early on near 40%. Later reports showed significant improvement in prognosis. A Spanish group reported a mortality of 8.3%. No deaths were reported to be related to JET in other later studies, likely from prompt identification and multipronged management approach. The etiopathogenesis, diagnosis, and management are reviewed below.

**ETIOPATHOGENESIS**

Abnormal automaticity is considered to be the primary underlying mechanism. Much research has focused on the risk factors for developing postoperative JET, including type of underlying heart disease, surgical procedures and CPB times, genetics, and electrolyte disturbances.

Conflicting literature exists as to the nature of surgeries associated with the highest incidence [Table 1], supporting the multifactorial model of etiology. Although the incidence is higher in some diseases than others, the nature of surgeries associated with higher incidence varies from center to center. This can partly be explained by the type/spectrum of surgeries each center is performing. Even for the same lesion, the incidence varies from center to center.

Factors contributing include direct surgical injuries such as myocardial incision, sutures close to the conduction system, trauma to conduction system during surgical handling, and cardiac volume and pressure fluctuations. CPB with ischemia-reperfusion and the related cellular biochemical effects, electrolyte shifts, and catecholamine administration can affect the stability of the cellular membrane and result in an increased myocardial irritability and automaticity. Inflammatory mediators released in the early postoperative period can alter the membrane potential of myocytes. This can also facilitate micro-reentry within the atrium and the AV node. The effects of CPB on release of inflammatory mediators such as histamine and eosinophil cationic protein by basophils and their relation to postoperative arrhythmias including JET were shown by Seghaye et al. Estradiol inhibits the release of inflammatory cytokines. It is supposed to have a protective effect against arrhythmias. Younger age is one of the commonly implicated risk factors for postoperative arrhythmias. Smaller hearts are subjected to more trauma during surgery, direct and indirect. The higher complexity of corrective infant heart surgeries could also explain higher incidence (14.3%) after infant heart surgery. Several studies have also shown that more than the anatomic substrate or the type of surgery, longer CPB times are the predictive of postoperative arrhythmias including JET. Complexity indirectly indicates longer ischemic times, more reperfusion injury, and more inflammatory response. Surgical procedures remote from the AV node like resection of sub aortic stenosis, atrial septal defect closure and cardiac transplantation has also been associated with...
In rat studies, HCN channels upregulated in a specific CHD unrelated to the iatrogenic factors, but predisposing to JET, are plausible. Angiotensin-converting enzyme deletion polymorphism is reportedly associated with more than two times increase in the odds of developing JET, suggesting the potential role of renin-angiotensin-aldosterone system.

Hyperpolarization-activated cyclic nucleotide-gated (HCN) channel upregulation may play a role in the genesis of JET. They are found not only in the SA node AV node but also in the conduction system of the myocardium which includes His bundle and Purkinje fibers. Although their presence is of no physiological significance in the normal myocardium, HCN channels are upregulated in remodeling of ischemia, hypertrophy, and heart failure. In rat studies, HCN channels upregulated within a day after myocardial infarction. A similar change is plausible after CPB. Notwithstanding CPB, CHD patients have hemodynamically significant lesions, which negatively affect the ventricle by remodeling, and can upregulate HCN channels in the conduction system, predisposing them to arrhythmias. Triggers and modulators such as electrolyte imbalance and excess catecholamine acting on the electrically remodeled ventricle with upregulated HCN channels might explain JET after surgeries without any possibility of mechanical injury to conduction system and no CPB, such as Fontan and the Blalock-Taussig-Thomas shunt.

Electrolyte imbalances, prominently hypomagnesemia, have been implicated. The literature on hypomagnesemia and JET is conflicting. Nevertheless, the role of magnesium in preventing JET was reinforced by a prospective randomized double-blind study of the effect of magnesium supplementation on arrhythmias after CPB. This study was terminated prematurely because of the unacceptable incidence of hemodynamically significant JET in the placebo group.

**DIAGNOSIS**

JET can be diagnosed on surface ECG. “JET is best defined as a tachycardia originating from the AV junction with gradual onset, gradual offset, rate variability, narrow QRS complex, usually with a ventricular rate faster than the atrial rate and AV dissociation.” The heart rate in JET is variably defined as a junctional rate >95th percentile of heart rate for age or more than 170 beats per minute. The latter definition is handy from a practical viewpoint. Invasive electrophysiological study is rarely needed. The electrophysiological hallmark of JET is that each QRS complex is preceded by a His bundle depolarization. Except when there is underlying conduction system disease, the His ventricular interval is normal. Ventriculoatrial conduction block and AV dissociation are the common findings, but ventriculoatrial conduction can sometimes be seen. JET has spontaneous initiation and termination. As an automatic focus tachycardia, JET cannot be terminated by direct current cardioversion, by critically timed premature beats, or by overdrive pacing. Failure to convert the “SVT” with DC cardioversion should be taken as evidence in favor of JET or other automatic tachycardias (such as ectopic atrial tachycardia). Temporary atrial wires can be used to display an atrial lead ECG for additional information. [Figure 2 - atrial electrogram]. This is helpful when atrial depolarization is not visible on surface ECG, the relation between atrial and ventricular electrical activity is unclear on surface ECG, wide QRS tachycardia needs to be better defined, or whenever the mechanism of arrhythmia is unclear. Adenosine will not terminate the arrhythmia but block conduction to the atria, resulting in VA dissociation. In patients with clear presence of AV dissociation during the arrhythmia, there is little diagnostic benefit to adenosine. However, in those with 1:1 conduction to the atrium, adenosine can be used to unmask AV dissociation and confirm the diagnosis of JET.

---

**Table 1: Surgeries reported to be associated with high incidence of junctional ectopic tachycardia**

| Study                  | Surgeries most commonly reported to be associated with JET |
|------------------------|----------------------------------------------------------|
| Batra et al.[27]       | Arterial switch operation 23% (n=13), AV canal repair 21% (n=19), and Norwood repair 20% (n=10) |
| Delaney et al.[28]     | Complete AV septal defect repair 72% (n=11), arterial switch 62.5% (n=8) |
| Pfammatter et al.[29]  | Ventricular septal defect 30% (n=75), tetralogy of Fallot 35% (n=52), AV canal 47% (n=45) |

AV: Atrioventricular, JET: Junctional ectopic tachycardia
The ventricular rate can be irregular with sinus capture beats when appropriately timed P waves conduct to the ventricles. Rarely, there can be 1:1 retrograde VA conduction, with a ventricular rate equal to atrial rate, and when this happens, it may be difficult to distinguish JET from other forms of supraventricular tachycardia. If P waves are not identifiable, ECG can mimic appearance of atrial fibrillation. The QRS complex is similar in morphology to baseline sinus beats and can be wide when there is underlying bundle branch block on baseline ECG. If so, it may be difficult to distinguish JET from ventricular tachycardia.

**MANAGEMENT**

A recent European survey reflected the widely practiced multipronged approach. The antiarrhythmic of choice was amiodarone, used in varying sequential order with therapeutic hypothermia and pacing. Table 2 summarizes published management strategies from the literature. So far, no significant differences in hard outcomes between the small groups have been detected. Given the widespread acute effects and probable long-term sequelae of any period of low cardiac output, it seems prudent to start early aggressive therapy to control/convert JET before signs of low cardiac output ensue. Patients with low cardiac output at onset of JET were found to have a predilection for amiodarone unresponsiveness. These patients as well as patients deemed to be otherwise at high risk of same would require combined therapy with hypothermia and pharmacological agents [Figure 3]. Restoration to sinus rhythm is the ideal target of treatment. This might not always be readily achievable. A decrease in heart rate adequate for hemodynamic improvement or one that allows atrial or AV sequential pacing, and thereby improving cardiac output is generally considered as success of treatment. This is in the background that JET is a self limiting disorder, resolving in 48-72 hours or a week. Inadequate response warrants consideration of newer agents such as ivabradine/sotalol. Stable patients can be started on either hypothermia or pharmacotherapy but need to be vigorously monitored for response and treatment escalated as needed. It was noted in a small group of patients that when the heart rate exceeded 200 beats/min for 5 h, congestive heart failure and clinical signs of low cardiac output manifested. The window from onset of JET to low cardiac output syndrome is highly variable. Hence, it is inappropriate to wait for more than a few hours for response to initial treatment modality. General measures, pacing, hypothermia, and pharmacotherapy including newer agents ivabradine/sotalol are discussed in more detail below.

**General measures**

General measures to be instituted include correction of fever, electrolyte abnormalities, with specific emphasis on magnesium, anemia and hypovolemia, optimizing sedation and pain control, and reducing inotropic drugs to the minimum tolerated dose. Although catecholamines can be considered as a group and tachycardia as a class effect, a lower threshold for

| Author                  | Management protocol                                                                 | Comments                                                                                                      | Mortality                  |
|-------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|---------------------------|
| Hoffman et al. [22]     | Staged approach - general measures first (avoidance of hypothermia - antipyretic agents and removal of external sources of radiant warming, sedation, and minimizing catecholamines) and specific therapy (amiodarone/pacing/active cooling) upon physiologic signs of low cardiac output | 13/33 (39.4%) of the patients received specific therapy                                                        | No death attributable to JET |
| Batra et al. [27]       | Conventional measures (cooling and sedation) as first-line intravenous amiodarone if no response | 48% (n=13) responded to conventional measures; 48% (n=13) required intravenous amiodarone therapy               | 1 death attributable to JET |
| Delaney et al. [28]     | General measures and atrial overdrive pacing through temporary atrial wires to restore synchrony if the ventricular rate permitted. Amiodarone infusion if ventricular rate was too rapid for effective overdrive pacing | Study was aimed mainly to determine incidence and risk factors                                                 | No death attributable to JET |
| Walsh et al. [29]       | Staged approach involving A reduction of catecholamines Correction of fever Atrial pacing to restore synchrony Digoxin Phenytoin or propranolol or verapamil Procainamide or hypothermia Combined procainamide and hypothermia | Last 30 patients achieved rapid control with early hypothermia and procainamide in addition to general measures and AV synchrony Treatment effective in 70/71 patients. General measures alone effective in 24%, hypothermia effective in 21%, Combined hypothermia and procainamide provided most reliable reduction of JET rate was the sole effective therapy for nearly 50% | 1 death attributable to JET |
| Kovacikova et al. [30]  | Amiodarone as first line after general measures if they failed to bring down the rate below 170 beats/min, hypothermia as second line | Amiodarone was effective in 18/40 patients (45%), 22/40 patients (55%) required escalation therapy to hypothermia | No death attributable to JET |

AV: Atrioventricular; JET: Junctional ectopic tachycardia

**Table 2: Management strategies mentioned in literature**

Sasikumar, et al.: Junctional ectopic tachycardia
It has been demonstrated that several techniques of individually optimized temporary dual chamber pacing, leading to optimal AV synchrony and/or synchronous ventricular contraction, can be successfully used to improve hemodynamics in patients with heart failure and selected dysrhythmias after congenital heart surgery. As discussed previously, slowing of JET to an acceptable heart rate that allows hemodynamic improvement with atrial or AV sequential pacing is often defined as success of any particular form of therapy for JET. This also highlights the fact that restoring AV synchrony by using different modes of pacing is an integral part of management of JET. It has been demonstrated that several techniques of individually optimized temporary dual chamber pacing, leading to optimal AV synchrony and/or synchronous ventricular contraction, can be successfully used to improve hemodynamics in patients with heart failure and selected dysrhythmias after congenital heart surgery.

Atrial pacing, AV sequential pacing, R wave synchronized atrial pacing, and paired ventricular pacing are all modalities that can be adapted keeping in mind its proven association in a multivariate analysis. The same study found an association with milrinone in univariate analysis. Milrinone and other vasodilators may accelerate rate by production of endogenous catecholamines. The association could also be attributed to complex nature of surgeries, where milrinone use is frequent.

It is important to avoid DC cardioversion if possible. It does not “convert” JET to normal rhythm and causes unnecessary cardiac trauma in a vulnerable postoperative child.

**The importance of atrioventricular synchrony and its restoration by pacing**

Most treatment methods described are better at slowing the JET rate rather than converting it to normal sinus rhythm. Even if rate is reduced, AV dissociation or ventriculoatrial conduction remains, resulting in atrial contraction almost coincident with ventricular contraction. Cardiac output can be significantly increased in the sick heart by the addition of atrial contraction at correct time in cardiac cycle even though cardiac output in small children is predominantly rate dependent. As discussed previously, slowing of JET to an acceptable heart rate that allows hemodynamic improvement with atrial or AV sequential pacing is often defined as success of any particular form of therapy for JET. This also highlights the fact that restoring AV synchrony by using different modes of pacing is an integral part of management of JET. It has been demonstrated that several techniques of individually optimized temporary dual chamber pacing, leading to optimal AV synchrony and/or synchronous ventricular contraction, can be successfully used to improve hemodynamics in patients with heart failure and selected dysrhythmias after congenital heart surgery.

Atrial pacing, AV sequential pacing, R wave synchronized atrial pacing, and paired ventricular pacing are all modalities that can be helpful in achieving hemodynamic stability.

Atrial pacing at a rate higher than JET rate can restore AV synchrony in a subset of patients with JET, accepting the disadvantages of a higher rate. In most patients, atrial pacing is successfully conducted to the ventricles through the AV node restoring AV synchrony. In rare cases, impaired AV conduction may be present and is revealed after institution of atrial pacing making AV resynchronization by atrial pacing impossible. In such cases, AV sequential pacing should be used. Since, by necessity, the paced rate will have to be higher than the JET rate, pacing may be disadvantageous unless hypothermia/pharmacological measures bring down the JET rate. Other drawbacks while using AV sequential pacing include ventricular dyssynchrony and contractile incoordination induced by ventricular pacing. R wave synchronized atrial pacing was suggested to overcome the disadvantages of AV sequential pacing. This was first reported to be achieved by using two stimulators in concert – one to receive input from ventricle and other to pace the atrium after a preset delay. Later, in the same study, a dual chamber analyzer (Medtronic) was used, the ventricular temporary pacing wires were connected to the atrial input, and the atrial wires were attached to the ventricular output in the VDD pacing mode with an AV delay set so that the atrial pacing stimulus preceded the subsequent QRS complex by an appropriate interval.

Janousek et al. successfully used a modified, commercially available temporary dual chamber pacemaker for R wave synchronized atrial pacing. R wave synchronized atrial pacing was performed using the VAT mode with inverse connection of the pacing wires (effectively AVT mode), short postventricular atrial refractory period (100 ms), and long AV (effectively VA) delay. Complications, especially pacemaker-mediated tachycardia, were easily stopped by prolongation of AV (effectively VA) delay. Atrial flutter induced by asynchronous atrial pacing during the VAT (effectively AVT) mode was managed by overdrive pacing. Significant hemodynamic benefit was achieved due to optimal AV resynchronization at intrinsic heart rate and spontaneous ventricular activation sequence.

Paired ventricular pacing is another modality that can be used to lower effective ventricular rate in patients with JET.
with postoperative JET.\textsuperscript{[66-68]} Pairs of stimuli are applied, second one shortly after the effective refractory period of first one. Electrical activation occurs from the second stimulus, but no mechanical contraction. This produces a postextrasystolic potentiation type effect on the next first stimulus, increasing cardiac output. Pacing protocols are generated using an electrophysiology simulator, which would be connected to ventricular leads. Disadvantages include the risk of ventricular fibrillation, inability to re-establish AV synchrony, and induction of ventricular dyssynchrony by single site ventricular pacing. Practicality is limited as it would require a sophisticated EP lab style simulator. Paired ventricular pacing can be reserved for acute management of patients with a high junctional rate precluding R wave synchronized atrial pacing or AV sequential pacing.\textsuperscript{[65]}

**Hypothermia**

JET is unresponsive to cardioversion and commonly used drugs like digoxin, beta blockers and calcium channel blockers. This stems from the underlying mechanism of enhanced automaticity. Hypothermia supresses cellular automaticity and was introduced for treatment of JET before amiodarone became widely accepted. It continues to be an important tool in management.\textsuperscript{[69]} It is often used in combination with pharmacotherapy/pacing.\textsuperscript{[32,54,56,61,70-73]} In normal subjects, hypothermia reduces cardiac output and oxygen demand and increases systemic vascular resistance. Hence, oxygen supply/demand is unaffected, provided shivering response is abolished by paralysis and mechanical ventilation.\textsuperscript{[71,74]} Accordingly, all cooling protocols require sedation, paralysis, and mechanical ventilation. Hypothermia is induced by application of ice packs, cooling blankets, fans, lavage using cold physiological saline through nasogastric tube or by intravenous induction using cold saline.\textsuperscript{[54,73]} Cooling is usually done to a core temperature (rectal) of 32°C–34°C for 24–36 h. Lesser degrees of hypothermia can be used in milder cases. Re-warming is started once the patient is stable for at least 24 h. Resolution of arrhythmia is not the criterion for re-warming. Hypothermia helps in reducing the heart rate effectively such that the restoration of AV synchrony by pacing is possible.\textsuperscript{[56,72,73,74]} Although hypothermia is known to suppress immune response, none of the studies reported an increase in infections; neither did they report metabolic acidosis nor electrolyte imbalances attributable to hypothermia.\textsuperscript{[34]} Hypothermia is a safe and effective method for reducing tachycardia rate adequate enough to improve hemodynamics.

**Pharmacotherapy**

Minimal negative inotropy and success in congenital JET led to use of amiodarone in postoperative setting.\textsuperscript{[54,57]} A randomized double blind study of amiodarone in pediatric population, 37% of which were post operative patients, half of whom had JET demonstrated the efficacy as well as safety concerns of amiodarone.\textsuperscript{[56]} Dose-related adverse events included hypotension (36%), vomiting (20%), bradycardia (20%), AV block (15%), and nausea (10%).\textsuperscript{[56]} Two postoperative deaths were supposed to be related to the drug as well. Other nonrandomized studies showed better efficacy and safety profile and amiodarone has emerged as the first-line agent.\textsuperscript{[55,54,56,57,75-77]} Hypotension is frequent and is usually responsive to volume expansion or calcium. Increase in inotrope dose may be required. Variation in dosing of amiodarone is a common practice to counter this, often omitting the loading dose and using a slow infusion.\textsuperscript{[59]} High AV oxygen saturation difference was an independent, significant risk factor for amiodarone failure and need of escalation therapy.\textsuperscript{[85]}

Procainamide, a class IA anti-arrhythmic, has also been used successfully.\textsuperscript{[50,78]} The active metabolite N-acetyl procainamide has class III antiarrhythmic properties. A higher bolus dose and a faster uptitration resulted in more effective control.\textsuperscript{[70]} Blood pressure remained stable or increased and central venous pressure remained stable or decreased in all patients. There was no mortality related to JET in this study.\textsuperscript{[78]} Hypotension is supposed to occur from ganglionic blockade at higher plasma concentrations, rather than negative inotropic effect which is minimal. Procainamide requires blood level monitoring.

Dexmedetomidine has a potential role in the acute phase of perioperative atrial and junctional tachyarhythmias for heart rate control and conversion to sinus rhythm. Incidence of adverse events is 28%, mostly hypotension and rarely AV block.\textsuperscript{[79]} In a more recent analysis of children undergoing surgical closure of ventricular septal defect, preincision initiation of dexmedetomidine, and continuation in postoperative period significantly decreased JET, as opposed to postoperative use.\textsuperscript{[80]} Nifekalant hydrochloride, a class III anti-arrhythmic approved in Japan, has been reported to be useful in case reports.\textsuperscript{[81]}

**Newer agents**

Sotalol has class III anti-arrhythmic properties similar to amiodarone and N-acetyl procainamide. It has been reported to be useful in intravenous form in a dose of 1 mg per kg over 1 h for postoperative JET.\textsuperscript{[82]} Sotalol does not require monitoring of plasma levels. The side effect and performance profile compared to amiodarone and procainamide need to be ascertained.

The latest tool in the armamentarium is ivabradine.\textsuperscript{[83-85]} Ivabradine is recommended for select adults with chronic stable angina, heart failure, and inappropriate sinus tachycardia. Ivabradine acts through HCN channels which may play an important role in etiopathogenesis. The major advantage of ivabradine, particularly in the postoperative patient, is its hemodynamic profile, where heart rate reduction is achieved without modifying inotropy, lusitropy, and intracardiac conduction as
opposed to other drugs. In small case series, ivabradine has been found to be effective as an adjunct to amiodarone and as the sole agent. Rate control is the initial response, followed by conversion to sinus rhythm. Early administration before hemodynamic compromise ensues will be key as absorption will be affected once cardiac output is compromised. These promising results warrant larger, randomized studies comparing it to amiodarone.

Digoxin, beta-blockers, and calcium channel blockers are classically considered ineffective for JET. Class IC agents – propafenone and flecainide – were also shown to be effective. However, in addition to nonavailability of intravenous formulations, negative inotropic effects and proarrhythmic potential limit their use.

**SUMMARY**

JET is a common arrhythmia in the pediatric cardiac postoperative setting, arising from enhanced automaticity of His bundle. Multiple factors have been found to be associated. Diagnosis is usually made on surface ECG; atrial electrograms are helpful in diagnostic dilemma. JET has devastating effects on postoperative hemodynamics. Prompt recognition and immediate institution of appropriate treatment (and avoidance of treatments like DC shock which is ineffective and likely counterproductive) are important. In addition to general measures such as correction of fever, electrolyte abnormalities, anemia and hypovolemia, optimizing sedation and pain control, and reducing inotropic drugs, therapeutic hypothermia and pharmacotherapy help controlling JET. Amiodarone is currently the preferred pharmacologic agent; ivabradine appears promising. Pacing restores AV synchrony augmenting CO. Recognition of the negative effect of JET on postoperative hemodynamics and advances in management have significantly reduced mortality and morbidity. Large multicenter randomized controlled trials comparing pharmacotherapy, hypothermia, and combined pharmacotherapy and hypothermia with restoration of AV synchrony by pacing in all arms as soon as rate allows are needed. Considering that JET has a high rate of spontaneous resolution, and that success rates across various modalities are similar, time to JET resolution should be considered as a better outcome variable along with response rates in future studies.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.
the tachycardia focus in patients with nonreentrant junctional tachycardia. Am J Cardiol 1996;78:1292-7.

16. Wu MH, Lin JL, Chang YC. Catheter ablation of junctional ectopic tachycardia by guarded low dose radiofrequency energy application. Pacing Clin Electrophysiol 1996;19:1655-8.

17. Ehler FA, Goldberger JJ, Deal RJ, Benson DW, Kadish AH. Successful radiofrequency energy ablation of automatic junctional tachycardia preserving normal atrioventricular nodal conduction. Pacing Clin Electrophysiol 1993;16:54-61.

18. Young M, Mehta MB, Martinez RM, Wolff GS, Gelband H. Combined alpha-adrenergic blockade and radiofrequency ablation to treat junctional ectopic tachycardia successfully without atrioventricular block. Am J Cardiol 1993;71:883-5.

19. Fishberger SB, Rossi AF, Messina JJ, Saul JP. Successful radiofrequency catheter ablation of congenital junctional ectopic tachycardia with preservation of atrioventricular conduction in a 9-month-old infant. Pacing Clin Electrophysiol 1998;21:2132-5.

20. Henneved H, Hutter P, Bink-Boelkens M, Sreeram N. Junctional ectopic tachycardia evolving into complete heart block. Heart 1998;80:627-8.

21. Grosse-Wortmann L, Kreitz S, Grabitz RG, Vazquez-Jimenez JF, Messmer BJ, von Bernuth G, et al. Prevalence of and risk factors for perioperative arrhythmias in neonates and children after cardiopulmonary bypass: Continuous holter monitoring before and for three days after surgery. J Cardiothorac Surg 2010;5:85.

22. Hoffman TM, Bush DM, Wernovsky G, Cohen MI, Weand TS, Gaynor JW, et al. Postoperative junctional ectopic tachycardia in children: Incidence, risk factors, and treatment. Ann Thorac Surg 2002;74:1607-11.

23. Dodge-Khatami A, Miller OL, Anderson RH, Gil-Jaurena JM, Goldman AP, de Leval MR. Impact of junctional ectopic tachycardia on postoperative morbidity following repair of congenital heart defects. Eur J Cardiothorac Surg 2002;21:255-9.

24. Haas NA, Plumpton K, Justo R, Jalali H, Pohlner P. Postoperative junctional ectopic tachycardia (JET). Z Kardiol 2004;93:371-80.

25. Mee RB. Surgical substrates of postoperative junctional ectopic tachycardia in congenital heart defects. J Thorac Cardiovasc Surg 2002;123:615-6.

26. Rekawek J, Kansy A, Miszczak-Knecht M, Manowska M, Bieganowska K, Brzezinska-Paszke M, et al. Risk factors for cardiac arrhythmias in children with congenital heart disease after surgical intervention in the early postoperative period. J Thorac Cardiovasc Surg 2007;133:900-4.

27. Batra AS, Chun DS, Johnson TR, Maldonado EM, Kashyap BA, Maiers J, et al. A prospective analysis of the incidence and risk factors associated with junctional ectopic tachycardia following surgery for congenital heart disease. Pediatr Cardiol 2006;27:51-5.

28. Delaney JW, Molteko JM, Dziura JD, Kopf GS, Snyder CS. Early postoperative arrhythmias after pediatric cardiac surgery. J Thorac Cardiovasc Surg 2006;131:1296-300.

29. Dodge-Khatami A, Miller OL, Anderson RH, Goldman AP, Gil-Jaurena JM, Elliott MJ, et al. Surgical substrates of postoperative junctional ectopic tachycardia in congenital heart defects. J Thorac Cardiovasc Surg 2002;123:624-30.

30. Pfammatter JP, Bachmann DC, Wagner BP, Pavlovic M, Berdat P, Carrel T, et al. Early postoperative arrhythmias after open-heart procedures in children with congenital heart disease. Pediatr Crit Care Med 2001;2:217-22.

31. Krongrad E. Postoperative arrhythmias in patients with CHD. Chest 1984;85:107-13.

32. Bash SE, Shah JJ, Albers WH, Geiss DM. Hypothermia for the treatment of postsurgical greatly accelerated junctional ectopic tachycardia. J Am Coll Cardiol 1987;10:1095-9.

33. Case CL, Gillette PC. Automatic atrial and junctional tachycardias in the pediatric patient: Strategies for diagnosis and management. Pacing Clin Electrophysiol 1993;16:1323-35.

34. Mosquera Pérez I, Rueda Núñez F, Medrano López C, Portela Torrón F, Zavanella Botta C, Castro Beiras A. Management by hypothermia of junctional ectopic tachycardia appearing after pediatric heart surgery. Rev Esp Cardiol 2003;56:510-4.

35. Kovacikova L, Hakacova N, Dobos D, Skrak P, Zahorec M. Amiodarone as a first-line therapy for postoperative junctional ectopic tachycardia. Ann Thorac Surg 2009;88:616-22.

36. Pfammatter JP, Paul T, Ziemer G, Kallfelz HC. Successful management of junctional tachycardia by hypothermia after cardiac operations in infants. Ann Thorac Surg 1995;60:556-60.

37. Kylat RI, Samson RA. Junctional ectopic tachycardia in infants and children. J Arrhythm 2020;36:59-66.

38. Pfammatter JP, Wagner B, Berdat P, Bachmann DC, Pavlovic M, Pfenninger J, et al. Procedural factors associated with early postoperative arrhythmias after repair of congenital heart defects. J Thorac Cardiovasc Surg 2002;123:258-62.

39. Herzog L, Lynch C. Arrhythmias accompanying cardiac surgery. In: Lynch C 3rd, editor. Clinical Cardiac Electrophysiology. Philadelphia: JB Lippincott; 1994. p. 231-58.

40. Till JA, Ho SY, Rowland E. Histopathological findings in three children with His bundle tachycardia occurring subsequent to cardiac surgery. Eur Heart J 1992;13:709-12.

41. Valsangiocomo E, Schmid ER, Schüpbach RW, Schmidlin D, Molinari L, Waldvogel K, et al. Early postoperative arrhythmias after cardiac operation in children. Ann Thorac Surg 2002;74:792-6.

42. Seghaye MC. The clinical implications of the systemic inflammatory reaction related to cardiac operations in children. Cardiol Young 2003;13:228-39.

43. Seghaye MC, Duchateau J, Grabitz RG, Mertes J, Marcus C, Buro K, et al. Histamine liberation related to cardiopulmonary bypass in children: Possible relation...
to transient postoperative arrhythmias. J Thorac Cardiovasc Surg 1996;111:971-81.

44. Seghaye MC, Qing M, von Bernuth G. Systemic inflammatory response to cardiac surgery: Does female sex really protect? Crit Care 2001;5:280-2.

45. Borgman KY, Smith AH, Owen JP, Fish FA, Kannankeril PJ. A genetic contribution to risk for postoperative junctional ectopic tachycardia in children undergoing surgery for congenital heart disease. Heart Rhythm 2011;8:1900-4.

46. Zampi JD, Hirsch JC, Gurney JG, Donohue JE, Yu S, Lapage MJ, et al. Junctional ectopic tachycardia after infant heart surgery: Incidence and outcomes. Pediatr Cardiol 2012;33:1362-9.

47. Bharati S, Moskowitz WB, Scheinman M, Estes NA 3rd, Lev M. Junctional tachycardias: Anatomic substrate and its significance in ablative procedures. J Am Coll Cardiol 1991;18:179-86.

48. Chakraborty P, Rose RA, Nair K, Dowsn E, Nanthakumar K. The rationale for repurposing funny current inhibition for management of ventricular arrhythmia. Heart Rhythm 2021;18:130-7.

49. Mackiewicz U, Gerges JY, Chu S, Duda M, Dobrzynski H, Lewartowski B, et al. Ivabradine protects against ventricular arrhythmias in acute myocardial infarction in the rat. J Cell Physiol 2014;229:813-23.

50. Walsh EP, Saul JP, Sholler GF, Triedman JK, Jonas RA, Mayer JE, et al. Evaluation of a staged treatment protocol for rapid automatic junctional tachycardia after operation for congenital heart disease. J Am Coll Cardiol 1997;29:1046-53.

51. Fox ML, Burrows FA, Reid RW, Hickey PR, Laussen PC, Hansen DD. The influence of cardiopulmonary bypass on ionized magnesium in neonates, infants, and children undergoing repair of congenital heart lesions. Anesth Analg 1997;84:497-500.

52. Dittrich S, Germanakis J, Dahnert I, Stiller B, Dittrich H, Vogel M, et al. Randomised trial on the influence of continuous magnesium infusion on arrhythmias following cardiopulmonary bypass surgery for congenital heart disease. Intensive Care Med 2003;29:1141-4.

53. Manrique AM, Arroyo M, Lin Y, El Khoudary SR, Colvin L, Lichtenstein S, et al. Magnesium supplementation during cardiopulmonary bypass to prevent junctional ectopic tachycardia after pediatric cardiac surgery: A randomized controlled study. J Thorac Cardiovasc Surg 2010;139:162-9.e2.

54. Jorgenson JV, Rosenblatt A, Fish FA, Martinelli K, Lee W, Nadas AS. Magnesium supplementation in the prevention of arrhythmias in pediatric patients undergoing surgery for congenital heart defects. Am Heart J 2000;139:522-8.

55. Davignon A, Rautaharju P, Boiselle E, Soumis F, Megelas M, Choquette A. Normal ECG standards for infants and children. Pediatr Cardiol 1979;1:123-31.

56. Saul JP, Scott WA, Brown S, Marantz P, Acevedo V, Etheridge SP, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: A randomized, double-blind, antiarrhythmic drug trial. Circulation 2005;112:3470-7.

57. Raja P, Hawker RE, Chaikitpinyo A, Cooper SG, Lau KC, Nunn GR, et al. Amiodarone management of junctional ectopic tachycardia after cardiac surgery in children. Br Heart J 1994;72:261-5.

58. Preuss T, Wiegand DL. Atrial electrograms. In: Wiegand DJL, Carlson KK, editors. AACN Procedure Manual for Critical Care. 5th ed. St Louis, MO: Elsevier Saunders; 2005. p. 296-303.

59. Entenmann A, Michel M, Herberg U, Haas N, Kumpf M, Gass M, et al. Management of postoperative junctional ectopic tachycardia in pediatric patients: A survey of 30 centers in Germany, Austria, and Switzerland. Eur J Pediatr 2017;176:1217-26.

60. Gillette PC. Diagnosis and management of postoperative junctional ectopic tachycardia. Am Heart J 1989;118:192-4.

61. Till JA, Rowland E. Atrial pacing as an adjunct to the management of post-surgical His bundle tachycardia. Br Heart J 1991;66:225-9.

62. Garson A Jr., Moak JP, Smith RT Jr., Norton JB Jr. Usefulness of intravenous propafenone for control of postoperative junctional ectopic tachycardia. Am J Cardiol 1987;59:1422-4.

63. Bronzetti G, Formigari R, Giardini A, Frascaroli G, Gargiulo G, Picchio FM. Intravenous flecainide for the treatment of junctional ectopic tachycardia after surgery for CHD. Ann Thorac Surg 2003;76:148-51.

64. Janousek J, Vojtovic P, Chaloupecky V, Hucin B, Tlaskal T, Kostelka M, et al. Hemodynamically optimized temporary cardiac pacing after surgery for congenital heart defects. Pacing Clin Electrophysiol 2000;23:1250-9.

65. Janousek J, Vojtovic P, Gebauer RA. Use of a modified, commercially available temporary pacemaker for R wave synchronized atrial pacing in postoperative junctional ectopic tachycardia. Pacing Clin Electrophysiol 2003;26:579-86.

66. Waldo AL, Krongrad E, Kupersmith J, Levine OR, Bowman FO Jr., Hoffman BF. Ventricular paired pacing to control rapid ventricular heart rate following open heart surgery. Observations on ectopic automaticity. Report of a case in a four-month-old patient. Circulation 1976;53:176-81.

67. Sluysmans T, Moulin D, Jamin P, Rubay J, Vliers A, Dejonghe D. Ventricular paired pacing to control intractable junctional tachycardia following open heart surgery in a child. Intensive Care Med 1989;15:203-5.

68. Kohli V, Young ML, Perryman RA, Wolff GS. Paired ventricular pacing: An alternative therapy for postoperative junctional ectopic tachycardia in congenital heart disease. Pacing Clin Electrophysiol 1999;22:706-10.

69. Hoffmann BF. Temperature effects on cardiac transmembrane potentials. In: Dripps RD, editor. Physiology of Induced Hypothermia. Washington, DC: National Academy of Sciences; 1956. p. 302-26.

70. Sholler GF, Walsh EP, Mayer JE, Saul JP, Gamble WJ, Lang P. Evaluation of staged treatment protocol for...
postoperative rapid junctional tachycardia. Circulation 1988;78 Suppl 11:597

71. Balaji S, Sullivan I, Deanfield J, James I. Moderate hypothermia in the management of resistant automatic tachycardias in children. Br Heart J 1991;66:221-4.

72. Guccione P, Di Carlo D, Papa M, Pasquini L, Marino R, Carotti A, et al. Hypothermia treatment of junctional ectopic tachycardia after surgical repair of congenital heart defects. G Ital Cardiol 1990;20:415-8.

73. Kelly BP, Gajarski RJ, Ohye RG, Charpie JR. Intravenous induction of therapeutic hypothermia in the management of junctional ectopic tachycardia: A pilot study. Pediatr Cardiol 2010;31:11-7.

74. Sealy WC. Hypothermia: Its possible role in cardiac surgery. Ann Thorac Surg 1989;47:788-91.

75. Laird WP, Snyder CS, Kertesz NJ, Friedman RA, Miller D, Fenrich AL. Use of intravenous amiodarone for postoperative junctional ectopic tachycardia in children. Pediatr Cardiol 2003;24:133-7.

76. Plumpton K, Justo R, Haas N. Amiodarone for postoperative junctional ectopic tachycardia. Cardiol Young 2005;15:13-8.

77. Haas NA, Camphausen CK. Impact of early and standardized treatment with amiodarone on therapeutic success and outcome in pediatric patients with postoperative tachyarrhythmia. J Thorac Cardiovasc Surg 2008;136:1215-22.

78. Mandapati R, Byrum CJ, Kavey RE, Smith FC, Kveselis DA, Hannan WP, et al. Procainamide for rate control of postsurgical junctional tachycardia. Pediatr Cardiol 2000;21:123-8.

79. Chrysostomou C, Beerman L, Shiderly D, Berry D, Morell VO, Munoz R. Dexmedetomidine: A novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: A preliminary study. Anesth Analg 2008;107:1514-22.

80. Gautam NK, Turiy Y, Srinivasan C. preincision initiation of dexametomidine maximally reduces the risk of junctional ectopic tachycardia in children undergoing ventricular septal defect repairs. J Cardiothorac Vasc Anesth 2017;31:1960-5.

81. Sasaki T, Nemoto S, Ozawa H, Katsumata T, Ozaki N, Okumura K, et al. Successful administration of nifekalant hydrochloride for postoperative junctional ectopic tachycardia in congenital cardiac surgery. Kyobu Geka 2007;60:1022-6.

82. Valdés SO, Landström AP, Schneider AE, Miyake CY, de la Uz CM, Kim JJ. Intravenous sotalol for the management of postoperative junctional ectopic tachycardia. Heart Rhythm Case Rep 2018;4:375-7.

83. Kumar V, Kumar G, Joshi S, Sharma V. Ivabradine for junctional ectopic tachycardia in post congenital heart surgery. Indian Heart J 2017;69:666-7.

84. Krishna MR, Kunde MF, Kumar RK, Balaji S. Ivabradine in post-operative junctional ectopic tachycardia (JET): Breaking new ground. Pediatr Cardiol 2019;40:1284-8.

85. Kumar V, Kumar G, Tiwari N, Joshi S, Sharma V, Ramamurthy R. Ivabradine as an adjunct for refractory junctional ectopic tachycardia following pediatric cardiac surgery: A preliminary study. World J Pediatr Congenit Heart Surg 2019;10:709-14.

86. Patel PA, Ali N, Roy A, Pinder S, Cubbon RM, Kearney MT, et al. Effects of ivabradine on hemodynamic and functional parameters in left ventricular systolic dysfunction: A systematic review and meta-analysis. J Gen Intern Med 2018;33:1561-70.

87. Kuck KH, Kunze KP, Schlüter M, Duckeck W. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia. Am J Cardiol 1988;62:37L-44L.

88. Heusch A, Kramer HH, Krogmann ON, Rammos S, Bourgeois M. Clinical experience with propafenone for cardiac arrhythmias in the young. Eur Heart J 1994;15:1050-6.